Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (3)

Search Parameters:
Keywords = argon laser photocoagulation

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
27 pages, 2706 KiB  
Review
Recent Innovations in Retinal Laser Therapy
by Mi Zheng and Yannis M. Paulus
Photonics 2025, 12(2), 156; https://doi.org/10.3390/photonics12020156 - 14 Feb 2025
Cited by 2 | Viewed by 2640
Abstract
The early history of retinal laser therapy began with the observation of solar blindness, leading to the development of various laser technologies for treating retinal diseases. The first retinal photocoagulation machine was developed in 1956, and subsequent advancements introduced ruby and argon lasers. [...] Read more.
The early history of retinal laser therapy began with the observation of solar blindness, leading to the development of various laser technologies for treating retinal diseases. The first retinal photocoagulation machine was developed in 1956, and subsequent advancements introduced ruby and argon lasers. While conventional theories posited that retinal damage was an indispensable prerequisite for therapeutic effects, emergent insights highlight the non-damaging mechanisms, such as photostimulation- and self-repair-related mechanisms. Novel therapies, such as subthreshold micropulse laser (SMPL) and selective retina therapy (SRT), are now being employed alongside innovative delivery systems to improve treatment efficiency and safety. Clinical studies are underway to evaluate the efficacy of these therapies for conditions like diabetic retinopathy and central serous chorioretinopathy. Despite the challenges in standardization and long-term evaluation, these innovations represent significant progress towards safer and more effective laser treatment for retinal diseases. Full article
(This article belongs to the Special Issue New Perspectives in Biomedical Optics and Optical Imaging)
Show Figures

Figure 1

17 pages, 19979 KiB  
Article
Neovascular Progression and Retinal Dysfunction in the Laser-Induced Choroidal Neovascularization Mouse Model
by Anna Salas, Anna Badia, Laura Fontrodona, Miguel Zapata, José García-Arumí and Anna Duarri
Biomedicines 2023, 11(9), 2445; https://doi.org/10.3390/biomedicines11092445 - 2 Sep 2023
Cited by 11 | Viewed by 6063
Abstract
The mouse model of laser-induced choroidal neovascularization (LI-CNV) has been widely used to study neovascular age-related macular degeneration; however, it still lacks a comprehensive characterization. Here, CNV was induced in the eyes of 12-week-old C57BL/6J male mice by argon laser irradiation. We studied [...] Read more.
The mouse model of laser-induced choroidal neovascularization (LI-CNV) has been widely used to study neovascular age-related macular degeneration; however, it still lacks a comprehensive characterization. Here, CNV was induced in the eyes of 12-week-old C57BL/6J male mice by argon laser irradiation. We studied the CNV lesion progression of an LI-CNV mouse cohort by using multimodal imaging (color fundus, optical coherence tomography (OCT), and fluorescence angiography, focal electroretinography features for 14 days, and related cytokines, angiogenic factors, and reactive gliosis for 5 days. CNV lesions involving the rupture of the Bruch’s membrane were confirmed using funduscopy and OCT after laser photocoagulation. During the initial stage, from the CNV induction until day 7, CNV lesions presented leakage observed by using fluorescence angiography and a typical hyperreflective area with cell infiltration, subretinal leakage, and degeneration of photoreceptors observed through OCT. This correlated with decreased retinal responses to light. Moreover, inflammatory and angiogenic markers were reduced to basal levels in the first 5 days of CNV progression. In contrast, reactive gliosis and the VEGF expression in retinal sections were sustained, with infiltration of endothelial cells in the subretinal space. In the second stage, between days 7 and 14 post-induction, we observed stabilization of the CNV lesions, a hyperfluorescent area corresponding to the formation of fibrosis, and a partial rescue of retinal function. These findings suggest that the LI-CNV lesion development goes through an acute phase during the first seven days following induction, and then the CNV lesion stabilizes. According to these results, this model is suitable for screening anti-inflammatory and anti-angiogenic drugs in the early stages of LI-CNV. At the same time, it is more convenient for screening anti-fibrotic compounds in the later stages. Full article
Show Figures

Figure 1

13 pages, 7421 KiB  
Review
Bullous Central Serous Chorioretinopathy: A Rare and Atypical Form of Central Serous Chorioretinopathy. A Systematic Review
by Francesco Sartini, Martina Menchini, Chiara Posarelli, Giamberto Casini and Michele Figus
Pharmaceuticals 2020, 13(9), 221; https://doi.org/10.3390/ph13090221 - 28 Aug 2020
Cited by 24 | Viewed by 5254
Abstract
Bullous central serous chorioretinopathy (bCSCR) is a rare variant of the central serous chorioretinopathy, complicated by an exudative retinal detachment with shifting fluid. This systematic review aims to present the epidemiology, the pathogenesis, the clinical presentation, the imaging, the differential diagnosis, and the [...] Read more.
Bullous central serous chorioretinopathy (bCSCR) is a rare variant of the central serous chorioretinopathy, complicated by an exudative retinal detachment with shifting fluid. This systematic review aims to present the epidemiology, the pathogenesis, the clinical presentation, the imaging, the differential diagnosis, and the latest treatments of this disease. A total of 60 studies were identified following a literature search adhering to PRISMA guidelines. After full-text evaluation, 34 studies about bCSCR were included. bCSCR usually affects middle-aged men, and the principal risk factor is corticosteroid medications. Pathogenesis is related to an increased choroidal vessel and choriocapillaris permeability, with subsequent subretinal fluid accumulation, rich in fibrin, which may provoke the exudative retinal detachment. Clinical presentation and imaging are fundamental to distinguish bCSCR from other pathologies, avoiding unappropriated treatment. Corticosteroid withdraws (if assumed) and laser photocoagulation of leakage sites seen at angiography may speed up retinal reattachment. Verteporfin photodynamic therapy, transpupillary thermal therapy, oral eplerenone and scleral thinning surgery are other therapeutic options. An early diagnosis might prevent disease progression due to harmful medications as well as unnecessary surgery. Full article
(This article belongs to the Special Issue Pharmacotherapy of Central Serous Chorioretinopathy)
Show Figures

Figure 1

Back to TopTop